Through facilitating clinical trial enrollment, the KCH lymphoma study has also shown that CHOP, R-CHOP, and modified EPOCH are safe, effective, and feasible treatment regimens for aggressive non-Hodgkin lymphoma (NHL) (29), diffuse large B-cell lymphoma (DLBCL) (30), and other high-risk NHLs, e.g., plasmablastic lymphoma (31), respectively. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.